• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Novan Presents New Data on Skin Disease Program

    Bryan Mc Govern
    Apr. 27, 2017 09:18AM PST
    Pharmaceutical Investing

    Novan announced new preclinical data for two studies with SB414 treating inflammatory skin diseases will be showcased Society for Investigative Dermatology conference.

    Novan (NASDAQ:NOVN) announced new preclinical data for two studies with SB414 treating inflammatory skin diseases will be showcased at the annual Society for Investigative Dermatology conference.
    As quoted in the press release:

    In a psoriasis mouse model, SB414 significantly (p<0.05) reduced composite psoriasis scores and also inhibited the production of pro-inflammatory cytokines, including interleukin-17, or IL-17a and IL-17f. Additionally, in two in vivo models that assess critical components of atopic dermatitis disease pathology, SB414 displayed potent anti-staphylococcal activity and dose-dependent inhibition of inflammation comparable to betamethasone, a mid-potency corticosteroid used to treat eczema patients.

    “Both psoriasis and atopic dermatitis patients are in need of new topical therapeutic options,” said Alan Menter, M.D., program director of dermatology residency and chair of dermatology for Baylor University, and dermatologist at Texas Dermatology Associates, P.A. “I am specifically intrigued by SB414’s effect on the proven psoriatic pathway IL23/IL17. The majority of new drugs for psoriasis over the past 12 years have been limited to systemic and biologic therapies. Approximately six million people in the United States, or 80% of all psoriasis sufferers, with mild to moderate disease have been treated purely with topical agents and have yet to benefit from our deeper understanding of the pathophysiology of the disease. These preclinical results give hope that there may be a therapeutically valuable, novel topical treatment that downregulates many of the key cytokines in the immunological cascade of psoriasis.”

    Novan plans to submit an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for SB414 in the second quarter of 2017 and initiate clinical development of the nitric oxide-releasing cream with a Phase 2 proof-of-concept trial in patients with mild-to-moderate psoriasis.

    Click here to read the full press release.

    Source: globenewswire.com

    pharmaceutical investinginvestigational new drug applicationatopic dermatitisnew drug applicationpreclinical datalate-stage pharmaceutical companyfood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    Row of test tubes and pipette with chemical droplet chemical coming from it.

    Top 5 Small-cap Biotech Stocks of 2025

    Invion Limited

    Invion Limited

    Latest News

    Orphan Drug Designation Granted by U.S. FDA for Anal Cancer

    Trading Halt

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×